Pharmacokinetics and Safety of Solid Oral Posaconazole (SCH 56592) in Subjects at High Risk for Invasive Fungal Infections (Phase 1b; Protocol No. P05615)
Latest Information Update: 15 Mar 2023
At a glance
- Drugs Posaconazole (Primary)
- Indications Mycoses
- Focus Pharmacokinetics
- Acronyms MK-5592-065/P05615
- Sponsors Merck Sharp & Dohme
- 09 Mar 2023 Results of pooled analysis of pharmacokinetic modeling study assessed whether hematopoietic stem cell transplant recipients, at increased risk of CDI and exhibiting decreased albumin levels within the first month posttransplant, are at risk of clinically relevant reductions in bezlotoxumab exposure from NCT01241552/NCT01513239, PN004, PN005, and PN006, NCT01777763 and NCT01691248 studies, published in the Clinical Therapeutics.
- 16 Apr 2014 New trial record